Intel stock spikes after report of possible US government stake
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd (NASDAQ:URGN), a company with impressive gross margins of 88.5% and a market capitalization of $902 million, sold 10,000 ordinary shares of the company on August 11, 2025. The shares were sold at a weighted average price of $17.69, for a total transaction value of $176,900. Prices for the sales ranged from $17.63 to $17.76. The stock has shown strong momentum, gaining over 82% in the past six months, though it typically trades with high volatility.
Following the transaction, Schoenberg directly owns 148,229 ordinary shares of UroGen Pharma Ltd. According to InvestingPro, the company maintains strong liquidity with a current ratio of 4.14, though analysts anticipate continued losses this year. For deeper insights and 8 additional ProTips about URGN, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, UroGen Pharma reported its second-quarter 2025 earnings, revealing a net loss of $1.50 per share, which was greater than the anticipated loss of $0.83 per share. The company achieved net product revenues of $24.2 million, surpassing the forecasted $23.13 million and marking an 11% increase year-over-year. Despite this revenue beat, H.C. Wainwright lowered its price target for UroGen Pharma to $40 from $50, while maintaining a Buy rating. The adjustment followed the financial results, which showed revenue falling short of the firm’s forecast of $25.9 million. Meanwhile, Guggenheim raised its price target on UroGen Pharma to $32 from $30, maintaining a Buy rating as well. This revision came in light of UroGen’s focus on the launch of Zusduri, approved in June for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Guggenheim noted the potential of Zusduri in a $5 billion U.S. market, with expectations of achieving over $1 billion in peak sales. These developments highlight the mixed analyst perspectives on UroGen Pharma’s recent performance and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.